Third Harmonic Bio

Third Harmonic Bio is a clinical-stage company developing a first-in-class, ultra-selective oral KIT inhibitor for the treatment of severe allergy and inflammation. The company’s lead candidate, THB001, is in clinical development for chronic urticaria and has the potential to treat a broad range of mast-cell mediated dermal, respiratory and gastrointestinal allergic and inflammatory diseases. Third Harmonic went public in September 2022 (NASDAQ: THRD).

Headquarters Cambridge, MA
Pipeline Phase 1
Twitter @3rdHarmonicBio
LinkedIn Third Harmonic Bio